In the Kaplan–Meier Plotter database, patients with ER + breast cancer with high NSDHL expression had a lower 10-year RFS rate (Probe ID 209279_s: n = 2561, HR = 1.22, 95% CI = 1.04–1.43, P = 0.014; Probe ID 215093: n = 2561, HR = 1.34, 95% CI = 1.14–1.57, P = 0.00027) compared to those with low NSDHL expression (Fig. S7). This evidence concerns the gene ESR1 and breast cancer.